1Gholam P, Kroehl V, Enk A H. Dermatology Life Quality In- dex and Side Effects after Topical Photodynamic Therapy of Ac- tinic Keratosis[J]. Dermatology, 2013.
4Inoue K, Fukuhara H, Kurabayashi A, et al.Photodynamic ther- apy involves an antiangiogenic mechanism and is enhanced by ferrochelatase inhibitor in urothelial carcinoma [J].Caneer sci- ence, 2013.
5Gaboriau F,Leray A M,Ropert M,et al.Effeets of deferasirox and deferiprone on cellular iron load in the human hepatoma cell line HepaRG[J].Biometals, 2010,23(2 ) : 231-245.
6Cappellini M D,Bejaoui M,Agaoglu L,et al.Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: efficacy and safety during 5 years" follow-up [J]. Blood, 2011,118(4) : 884-893.
二级参考文献34
1WOOD JC. Cardiac iron across different transfusion-dependent diseases[J]. Blood Rev, 2008,22 ( Suppl 2) : S14 - S21.
2MAMTANI M, KULKARNI H. Influence of iron chelators on my- ocardial iron and cardiac function in transfusion-dependent thalas- saemia: a systematic review and meta-analysis[ J]. Br J Haema- tol, 2008,141 (6) :882 - 890.
3BORGNA-PIGNATTI C, RUGOLOTTO S, DE STEFANO P, et al. Survival and complications in patients with thalassemia ma- jor treated with transfusion and deferoxamine[ J ]. Haematologi- ca, 2004,89(10) :1187 - 1193.
4TELFER P. Update on survival in thalassemia major[ J]. Hemo- globin, 2009,33 ( Suppl 1 ) :S76 - S80.
5CHATTERJEE R, BAJORIA R. New concept in natural history and management of diabetes mellitus in thalassemia major[J]. Hemoglobin, 2009,33 ( Suppl 1 ) :S127 - S130.
6CAPPELLINL MD, COHEN A, ELEFTHERIOU A, et al. Guideline for the clinical management of thalassemia 2nd revised edition[S]. Cyprus:Thalassemia International Federation,2008:46.
7OLIVIERI NF, NATHAN DG, MACMILLAN JH, et al. Survival in medically treated patients with homozygous beta-thalassemia [J]. N Engl J Med, 1994,331(9) :574 -578.
8MODELL B, KHAN M, DARLISON M. Survival in beta-thalas saemia major in the UK: data from the UK Tha|assaemia Registe1 [J]. Lancet, 2000,355(9220) :2051 -2052.
9MAGGIO A, D'AMICO G, MORABITO A, et al. Deferiprone versus deferoxamine in patients with thalassemia major: a ran- domized clinical trial [ J ]. Blood Cells Mol Dis, 2002,28 (2) : 196 -208.
10PENNELL DJ, BERDOUKAS V, KARAGIORGA M, et al. Randomized controlled trial of deferiprone or deferoxamine in be-ta-thalassemia major patients with asymptomatic myocardial sider- osis[J]. Blood, 2006,107(9) :3738 -3744.
2Soares B M,Resende M A,Silva D L,et al.In vitro photodynarnic inactivation of Candidaspp.growth and adhesion to buccal epithelial cells.J Photochem Photobiol B,2009,94(1):65-70.
3Wang X L,Wang H W,Wang H S,et al.Topical 5-aminolevulinic acid photodynamic therapy for the treatment of urethral condylomata acuminata.Br J Dermatol,2004,151(4):880-885.
4Kacerovska D,Pizinger K,Kumpova M,et al.Genital warts treated by photodynamic therapy.Skinmed,2007,6(6);295-297.
5Nestor M S.The use of photo dynamic therapy for treatment of acne vulgaris.Dermatol Clin,2007,25(1):47-57.
6Horfelt C,Stenquist B,Larko O,et al.Photodynarnic therapy for acne vulgaris:a pilot study of the dose-response and mechanism of action.Acta Derm Venereol,2007,87(4):325-329.
7Morgan J,Jackson J D,Zheng X,et al.Substrate affinity of photosensitizers derived from chlorophyll-a:the ABCG2 transporter affects the phototoxic response of side population stem cell-like cancer cells to photodynarnic therapy.Mol Pharm,2010,7(5):1789-1804.
8Omrani AS,Makkawy EA,Baig K,et al.Ten- year review of invasive Candida infections in a tertiary care center in Saudi Arabia[J].Saudi Med J,2014,35(8):821-826.
9Tellapragada C,Eshwara VK,Johar R,et al.Antifungal suscepti-bili- ty patterns,in vitro production of virulence factors,and evaluation of diagnostic modalities for the speciation of pathogenic Candida from blood stream infections and vulvovaginal candidiasis[J].J Pathog,2014(2014):1-8.
